Foghorn Therapeutics Inc. (FHTX) - 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. Foghorn Therapeutics Inc. is a clinical-stage biotechnology company developing precision medicines that target the chromatin regulatory system to treat serious diseases, primarily in oncology. The company utilizes its proprietary Gene Traffic Control® platform to identify and drug targets within this system. As of December 31, 2025, Foghorn had 106 employees and no products approved for commercial sale.
The company's most advanced asset is FHD-909, a selective SMARCA2 inhibitor developed in collaboration with Eli Lilly and Company. In October 2024, the first patient was dosed in a Phase 1 dose escalation trial for FHD-909 targeting SMARCA4-mutated non-small cell lung cancer (NSCLC). In December 2024, the company discontinued the independent development of FHD-286.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $30.9 | $22.6 |
| Research & Development Expenses | $85.5 | $94.5 |
| General & Administrative Expenses | $27.6 | $28.4 |
| Net Loss | $(74.3) | $(86.6) |
| Cash, Cash Equivalents & Marketable Securities | $158.9 | $243.7 |
| Accumulated Deficit | $(632.5) | $(558.2) |
Liquidity: As of December 31, 2025, the company held $158.9 million in cash, cash equivalents, and marketable securities. Management expects these resources to fund operations for at least 12 months from the filing date. The company has no debt obligations listed in the balance sheet.
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased by $8.3 million (37%) to $30.9 million, driven by continued advancement of programs under the Lilly Collaboration Agreement.
- Expense Reduction: Total operating expenses decreased by $8.0 million to $117.3 million. This was primarily due to a $10.2 million reduction in costs for the discontinued FHD-286 program and lower facility costs following a lease modification.
- Net Loss Improvement: Net loss narrowed by $12.3 million to $74.3 million, reflecting the decrease in operating expenses and a gain on lease modification of $1.6 million, partially offset by lower interest income.
- Asset Impairment: The company recorded a non-cash impairment charge of $5.9 million related to the abandonment of leasehold improvements during a relocation to new headquarters in Watertown, MA, in December 2025.
Guidance, Outlook, and Risks
Outlook: Foghorn expects to continue incurring significant operating losses for the foreseeable future. The company anticipates filing four Investigational New Drug Applications (INDs) over the next two years. Expenses are expected to increase as the company advances FHD-909 and other product candidates into clinical development.
Recent Capital Activity: In January 2026 (subsequent to the reporting period), the company completed an offering raising approximately $50.0 million in gross proceeds through the sale of common stock, pre-funded warrants, and series warrants.
Key Risks:
- Capital Needs: The company has an accumulated deficit of $632.5 million and will require substantial additional funding to sustain operations and advance its pipeline.
- Development Risk: Success depends heavily on the clinical performance of FHD-909 and other preclinical candidates. Clinical trials may fail to demonstrate safety or efficacy.
- Collaboration Dependency: The company relies on Eli Lilly for the development and commercialization of FHD-909 and does not have unilateral control over the development timeline or strategy for partnered programs.
- Intellectual Property: The company relies on trade secrets for its platform and has limited issued patents, creating risks regarding the ability to protect its technology.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $158.9 million cash balance against projected burn rates, considering the recent $50 million raise in January 2026.
- Revenue Recognition: Review the "cost-to-cost" method used to recognize revenue from the Lilly Collaboration Agreement and the sensitivity of revenue to changes in total estimated costs.
- FHD-909 Progress: Monitor upcoming data readouts from the Phase 1 dose escalation trial for FHD-909, which is the primary value driver.
- Lease Obligations: Assess the impact of the new Watertown lease (expiring 2035) and the associated $60.8 million in future minimum payments.
- Discontinued Programs: Confirm that costs associated with the discontinued FHD-286 program have been fully written off and will not recur.